
Zenex Animal Health acquires majority stake in Netherlands-based VievePharm
The Hindu
Zenex Animal Health acquires VievePharm to enhance global reach in natural animal nutrition and establish a European manufacturing hub.
Zenex Animal Health India Private Ltd, backed by Multiples PE has announced the acquisition of a majority stake in Netherlands-based VievePharm, a specialist in natural animal nutrition, for an undisclosed amount.
This would accelerate Zenex’s expansion into the global “naturals” market while establishing a dedicated manufacturing and sales hub in Western Europe, the company said.
This acquisition allows Zenex to utilise VievePharm’s established distribution network in the EU to accelerate the export of its broader therapeutic and nutritional range across multiple formulation types.
Dr. Arun Atrey, Managing Director and CEO of Zenex Animal Health, said, “The acquisition of VievePharm is a logical progression of our first-principles approach to animal healthcare — focusing on prevention and sustainable productivity.”
“By combining VievePharm’s advanced bolus technology and European market access with our R&D depth and global distribution, we are positioned to offer holistic, science-backed solutions that address the root causes of animal health challenges,” he added.
Manish Gaur, Board member, Zenex, and MD & Head of Pharma and Healthcare at Multiples, said, “Strategic acquisitions that provide important capability additions, like VievePharm’s bolus technology and European footprint, will continue to be a vital part of the value-creation journey at Zenex as we scale our leadership globally.”

Insurance penetration and density are often misunderstood and do not reveal how many families are insured or whether they would be financially secure if the main earning member were to die. The real issue is not reach but adequacy, as households may have life insurance but not enough cover to replace lost income, leaving them financially vulnerable.












